-

Thermo Fisher Scientific Completes Acquisition of MarqMetrix

Expands Raman Spectroscopy Portfolio with In-Line Process Analytical Technology

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has completed its acquisition of MarqMetrix, a privately held developer of Raman-based spectroscopy solutions for in-line measurement. The terms of the deal were not disclosed.

Based in Seattle, Washington, MarqMetrix provides innovative and fit-for-purpose in-line Process Analytical Technology (PAT), offering customers a simplified method to make precise and accurate measurements throughout the manufacturing process for a wide range of applications, including biopharma and pharmaceuticals, oil and gas, and chemicals and polymers.

“The acquisition of MarqMetrix is an excellent strategic fit for Thermo Fisher and adds highly complementary Raman-based in-line PAT to Thermo Fisher’s portfolio,” said Miguel Faustino, President, Chemical Analysis, Thermo Fisher. “MarqMetrix will add expanded and differentiated capabilities to Thermo Fisher’s leading portfolio of analytical solutions to address customer requirements for real-time measurement and process control of critical manufacturing process parameters that affect quality. We look forward to welcoming the MarqMetrix team to Thermo Fisher.”

MarqMetrix has approximately 30 employees based in the United States. MarqMetrix will become part of Thermo Fisher's Analytical Instruments segment.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Lisa Robillard
Thermo Fisher Scientific
Phone: +1-781-790-7324
E-mail: lisa.robillard@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Lisa Robillard
Thermo Fisher Scientific
Phone: +1-781-790-7324
E-mail: lisa.robillard@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center to Accelerate Breakthrough Therapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco. The new center provides pharmaceutical and biotechnology innovators with immersive, hands-on access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies. Accelerating Drug Discovery with Cryo-EM The...

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar**, new color-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species — including Candida auris, a growing global antimicrobial resistance (AMR) threat1. Invasive fungal infections are an increasing challenge for healthcare systems w...

Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection. For transplant recipients, finding the right tacrolimus dose as early as possible can be life-changing. If the dose is too low, the body may...
Back to Newsroom